Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition …

Purpose With the emergence of various novel therapies including new generation taxane
and androgen-targeted therapies, the optimal sequence of systemic treatment in metastatic …

Abstract Lessons Learned. Temsirolimus maintenance therapy after docetaxel induction
chemotherapy is safe in patients with castration-resistant prostate cancer, although …

OBJECTIVES: Docetaxel is considered first-line chemotherapy for patients with metastatic
castrate resistant prostate cancer (CRPC). Carboplatin and paclitaxel have demonstrated …

Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through
vascular endothelial growth factor (VEGF) have been shown to play important roles in …

Background Multiple factors can influence outcomes of patients receiving identical
interventions in clinical trials and in routine practice. Here, we compare outcomes of men …

Background. Mitoxantrone was approved for use in metastatic castrate-resistant prostate
cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase …

4508^ Background: The treatment of mCRPC following docetaxel (D) therapy failure due to
progressive disease (PD) or toxicity is an unmet medical need. TROPIC evaluated the …

Background Although new androgen-targeted therapies offer prolonged survival in
metastatic castration-resistant prostate cancer (CRPC), most men still face progressive …

Background Phosphatase and tensin homologue (PTEN) loss is common in advanced
prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus …